Filter by ContentType
Cellular immunotherapy—a matter of delivery?
Nina Bauer
05 September 2024
Viewpoint
Exploring the potential of combination radio-immunotherapy for a comprehensive cancer treatment
Zachary Morris
04 April 2024
Viewpoint
Unraveling combination therapies in lung cancer: oncogenic drivers, ICI resistance, and predictive biomarkers
Paul Hofman
27 March 2024
Viewpoint
Human capital comes with a memory
Helena Strigard
25 March 2024
Viewpoint
Optimal selection of tumor antigens
Sophie Papa
29 November 2023
Viewpoint
How to expedite clinical development of oncology agents: overcoming complexities of early-phase oncology trials for ATMPs
Harriet Gray Stephens
29 September 2023
Viewpoint
iNKT cells for allogeneic cell therapy
Eleni Chantzoura, Paul Ibbett
31 August 2023
Viewpoint
Achieving more patient-centered trials in cancer immunotherapy: a patient advocate perspective
Deborah Collyar
18 April 2023
Viewpoint
Advancing best-in-class allogeneic CAR-T therapies
Blair Madison
16 April 2023
Viewpoint
Customizing T cell biology: armoring approaches to optimize allogeneic CAR-T therapies
Jakob Dupont
28 November 2022
Viewpoint
Immune modulatory vaccines: the safe way to inflame the tumor microenvironment & guide anti-cancer immunotherapies
Mads Hald Andersen
14 October 2022
Viewpoint
Harnessing components of the immune system in bioengineered 3D tumor models
Aleksander Skardal
08 September 2022
Viewpoint
The power of combining iPSC-derived NK cell therapy & NK-cell engager antibodies
Dr Wei Li, Dr Daniel Teper
22 July 2022
Viewpoint
Recent gene-editing guidance from FDA – clarifies some gene-editing development questions with room for additional recommendations
Kathleen Candando, Karl Whitney
10 July 2022
Viewpoint
Redefining success: predicting checkpoint inhibitor toxicity to improve patient outcomes
Joanne Weidhaas
13 June 2022
Viewpoint
Understanding the evolving safety landscape in autologous and allogeneic CAR-T therapy
Elaine Murray McCracken
06 June 2022
Viewpoint
Update on antibody–drug conjugates: where are we now, & where are we going?
Fernanda Arnaldez
16 April 2022
Viewpoint
The end of an era of cancer drug discovery: life without new drug targets
Armen Mardiros, Alexander Kamb
12 April 2022
Viewpoint
Early-stage investment in immuno oncology: riding the waves of hope & hype
W Joost Lesterhuis, H Mikkelsen, J Tobin et al
15 March 2022
Viewpoint
Critical collaboration: Efforts to expand clinical trial eligibility
Jeff Allen
28 February 2022
Viewpoint
Driving CARs on the biomanufacturing road to clinical success
Chelsia Qiuxia Wang, Andy Hee-Meng Tan
10 January 2022
Viewpoint